287 related articles for article (PubMed ID: 37753093)
1. The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer.
Zohair B; Chraa D; Rezouki I; Benthami H; Razzouki I; Elkarroumi M; Olive D; Karkouri M; Badou A
Front Immunol; 2023; 14():1201632. PubMed ID: 37753093
[TBL] [Abstract][Full Text] [Related]
2. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
[TBL] [Abstract][Full Text] [Related]
3. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
5. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
7. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
[TBL] [Abstract][Full Text] [Related]
8. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
9. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
11. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein receptor promotes crosstalk between cell stemness and tumor immune microenvironment in breast cancer: a large data-based multi-omics study.
Yuan Q; Lu X; Guo H; Sun J; Yang M; Liu Q; Tong M
J Transl Med; 2023 Nov; 21(1):871. PubMed ID: 38037058
[TBL] [Abstract][Full Text] [Related]
13. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract][Full Text] [Related]
14. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
15. Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic Pathway Signatures.
Li J; Qiu J; Han J; Li X; Jiang Y
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360212
[TBL] [Abstract][Full Text] [Related]
16. CD1C is associated with breast cancer prognosis and immune infiltrates.
Chen X; Zhang J; Lei X; Yang L; Li W; Zheng L; Zhang S; Ding Y; Shi J; Zhang L; Li J; Tang T; Jia W
BMC Cancer; 2023 Feb; 23(1):129. PubMed ID: 36755259
[TBL] [Abstract][Full Text] [Related]
17. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
18. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
20. ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer.
Liu J; Wei Y; Wu Y; Li J; Sun J; Ren G; Li H
Front Immunol; 2021; 12():657950. PubMed ID: 33936088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
